Moneybags

WHAT NEXT FOR OVOCA BIO INVESTORS?

Date: July 25, 2024 - Moneybags

Tim McCutcheon

Tim McCutcheon


IN A surprise move after the failure of the clinical trials for Ovoca Bio’s Orenetide drug, the CEO, Kirill Golovanov, resigned last week. More surprising, perhaps. was the decision of American non-executive director Tim McCutcheon (previously a CEO of the company in its Ovoca Gold iteration) to step in as Golovanov’s replacement and also to… Read more »

To access this content, you must be a Phoenix subscriber.

Get access to The Phoenix online for as low as €1.50 per week. Read all the regular online only Phoenix stories AND receive the packed digital edition every fortnight (25 per year). Great value for so many inside stories!

Subscribe Now! I'm a Subscriber